Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Eli Lilly, Ocugen, UPS Rise Premarket; Domino's Pizza Falls

Published 12/15/2021, 07:57 AM
Updated 12/15/2021, 07:58 AM
© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Wednesday, December 15th. Please refresh for updates.

  • Eli Lilly (NYSE:LLY) stock rose 5.5% after the drug company raised its full-year 2021 profit and sales forecast, helped partly by a recent U.S. government contract for its Covid-19 antibody treatment.
  • Ocugen (NASDAQ:OCGN) stock rose 5.4% after the biotech company said it has data suggesting its Covid-19 vaccine could provide protection against both current and future variants of the virus.

  • Oracle (NYSE:ORCL) stock rose 0.2% after the U.S. tech giant announced it has opened cloud regions in Stockholm and Milan as the pandemic increased demand for cloud computing tools.
  • Digital World Acquisition Corp (NASDAQ:DWAC) stock rose 5% following the news that the video distribution platform Rumble signed a partnership agreement with Trump Media, Donald Trump’s new media company which is merging with DWAC.

  • Vir Biotechnology (NASDAQ:VIR) stock rose 5.7% after the drugmaker announced further data showing that its Covid-19 antibody therapy, developed in partnership with GlaxoSmithKline (NYSE:GSK), was effective against the Omicron variant.

  • United Parcel Service (NYSE:UPS) stock rose 1.1% after Citigroup (NYSE:C) upgraded its investment stance to ‘buy’ from ‘neutral, taking a more constructive stance on the delivery firm, and ranking it ahead of FedEx (NYSE:FDX).

  • Domino’s Pizza (NYSE:DPZ) stock fell 1.5% after Barclays (LON:BARC) downgraded the pizza firm to ‘underweight’ from ‘equal weight’, seeing its pandemic-era outperformance dwindling.

  • Albemarle (NYSE:ALB) stock fell 5% and Livent (NYSE:LTHM) stock fell 7.8% after Goldman Sachs (NYSE:GS) downgraded its stance on both lithium producers to ‘sell’ from ‘neutral’.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

 

Latest comments

https://www.reuters.com/business/healthcare-pharmaceuticals/lab-test-eli-lilly-regeneron-antibody-therapies-lose-out-against-omicron-2021-12-14/
The FED has engineered a catastrophe they can't prevent.  They went way too far in manufacturing this eCONomy and fraudulent stock market.  The bubble is floating towards the cactus patch.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.